Trial Profile
High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Amantadine (Primary) ; Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Oct 2023 Results published in the Journal of Neurology
- 01 Jul 2021 Results published in the European Journal of Neurology
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.